Prostate Cancer

The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.

The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.

The Royal Oak, Michigan-based startup will use the funding to support development and commercialization of its pan-disease diagnostic testing platform. 

For the six-month period ended June 30, the molecular diagnostic company's revenues fell to $10.9 million from $17.2 million in H1 2018.

Researchers focused on candidate genes near expression quantitative trait loci identified by combining cancer susceptibility SNPs and available transcriptomic data.

The test will be used to identify which metastatic, castration-resistant prostate cancer patients harbor germline BRCA mutations and will likely benefit from Lynparza.

The assays will combine genomic and gene expression analyses to better understand driver mutations in prostate, breast, and pancreatic cancers.

The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.